Physician profile
Michael Morrow
NPI 1114464039
$2,824.58
in general payments reported to CMS, 2019-2025
14 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,050 · 2022: $668 · 2023: $784 · 2024: $213 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,106.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $480.00 | 2021 | |
| Seagen INC. | $445.35 | 2021-2023 | Adcetris |
| Novocure INC. | $442.17 | 2021-2024 | Optune |
| Abbvie INC. | $264.87 | 2023 | |
| Kite Pharma, INC. | $186.37 | 2021-2022 | |
| Janssen Biotech, INC. | $148.35 | 2022-2023 | Darzalex, Tecvayli |
| Ucb, INC. | $131.97 | 2024 | Briviact |
| Adc Therapeutics America, INC. | $120.46 | 2023 | |
| Jazz Pharmaceuticals INC. | $119.74 | 2021 | |
| Btg International INC. | $117.99 | 2022 | |
| Pfizer INC. | $109.78 | 2025 | |
| Genzyme Corporation | $107.58 | 2023 | |
| Glaxosmithkline, LLC. | $100.69 | 2022 | |
| Amgen INC. | $49.26 | 2023 | Kyprolis, Xgeva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Morrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.